AstraZeneca India announced its entry into rare disease therapy in India. The company received regulatory approval for its ‘Selumetinib’ for patients in India. Globally, more than 400 million people are affected by rare diseases, and currently, there are 7,000 identified and recorded rare diseases. AstraZeneca has partnered the Organization of...